Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients

Journal of Chemotherapy

Volumn 18, Issue 4, 2006, Pages 421-424

  Boruban, M C ^a   Yasar, U ^b   Babaoglu, M O ^b   Sencan, O ^a   Bozkurt, A ^b  

^a 1st Department of Neurosurgery   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

CYP2C9; Drug drug interaction; Inhibition; Tamoxifen

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; LOSARTAN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG EFFECT; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY;

EID: 33749038611     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.4.421     Document Type: Article

References (21)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339 (22): 1609-1618.
2. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97 (1): 30-39.
3. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23 (11): 1897-1901.
4. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed) 1987; 295 (6606): 1141.
5. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989; 298 (6666): 93.
6. Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. BMJ 1989; 298 (6682): 1253.
7. Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995; 36 (5): 513-515.
8. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77 (1): 1-16.
9. Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60 (5): 337-342.
10. Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71 (1): 89-98.
11. Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301 (3): 945-952.
12. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41: 535-567.
13. Sekino K, Kubota T, Okada Y et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59 (8-9): 589-592.
14. Streetman DS, Bertino JS, Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10 (3): 187-216.
15. Allabi AC, Gala JL, Horsmans Y et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther 2004; 76 (2): 113-118.
16. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001; 69 (1): 41-47.
17. Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58 (4): 412-417.
18. Kortunay S, Bozkurt A, Basci NE, Kayaalp SO. Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers. Eur J Drug Metab Pharmacokinet 2002; 27 (3): 171-174.
19. Kortunay S, Bozkurt A, Basci NE, Brosen K, Kayaalp SO. Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers. Pharmacol Toxicol 2001; 89 (6): 331-334.
20. Coller JK. Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Clin Exp Pharmacol Physiol 2003; 30 (11): 845-848.
21. Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005; 6 (3): 241-257.